NCT03689465 is a Phase 4 clinical trial of ATG in Hematopoietic Stem Cell Transplantation, sponsored by Nanfang Hospital, Southern Medical University.

Who is sponsoring NCT03689465?

NCT03689465 is sponsored by Nanfang Hospital, Southern Medical University.

What drugs are being tested in NCT03689465?

Interventions in NCT03689465: ATG, CTX, Mycophenolate Mofetil, Ciclosporin A (CsA), methotrexate (MTX).

What condition does NCT03689465 study?

NCT03689465 studies Hematopoietic Stem Cell Transplantation.

Is NCT03689465 still recruiting?

NCT03689465 is currently status unknown. Last updated 28 October 2019.

Last reviewed 2019-10-28 · How we verify

NCT03689465

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis

Status unknown Phase 4 Last updated 28 October 2019

What this trial tests

Phase 4 trial testing ATG in Hematopoietic Stem Cell Transplantation in 260 participants. Status unknown.

Timeline

29 October 2018

Primary endpoint
30 September 2020

31 December 2020

Quick facts

Lead sponsor	Nanfang Hospital, Southern Medical University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	260
Start date	29 October 2018
Primary completion	30 September 2020
Estimated completion	31 December 2020
Sites	7 locations across China

Drugs / interventions tested

ATG — full drug profile →
CTX — full drug profile →
Mycophenolate Mofetil (MYCOPHENOLATE MOFETIL) — full drug profile →
Ciclosporin A (CsA) — full drug profile →
methotrexate (MTX) — full drug profile →

Conditions studied

Hematopoietic Stem Cell Transplantation — all drugs for Hematopoietic Stem Cell Transplantation →

Sponsor

Nanfang Hospital, Southern Medical University

Who can join

Adults 18 to 65, any sex, with Hematopoietic Stem Cell Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The granulocyte colony-stimulating factor (G-CSF)+antithymocyte globulin (ATG)-based protocols and posttransplantation cyclophosphamide (PTCy) protocols have been widely used for graft-versus-host disease (GVHD) prophylaxis in haploidentical related donor transplantation (haplo-HSCT). Nevertheless, severe acute GVHD remains an obstacle for haplo-HSCT. This study is aim to evaluate the efficacy of a modified protocol that includes PTCY and ATG in recipients of haplo-HSCT.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Adoptive T Cell Therapy Following Haploidentical Hematopoietic Stem Cell Transplantation.
Zhang P, Tey SK. · · 2019 · cited 11× · PMID 31447852 · DOI 10.3389/fimmu.2019.01854

Verify or expand the search:

Other trials of ATG

Trials testing the same drug.

NCT05669001 — A Study of TCD601 in de Novo Renal Transplant Recipients · Phase 2 · completed
NCT06108739 — ATG Plus Low-dose PT-Cy for GVHD Prevention · Phase 3 · terminated
NCT05917405 — Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT · Phase 2 · recruiting
NCT05739630 — M-PTCy vs BuCy in Haploidentical HSCT for Acute Leukemia · Phase 2, PHASE3 · unknown
NCT05634915 — Clinical Study of rATG Individualized Administration in Haploidentical Hematopoietic Stem Cell Transplantation · Phase 4 · unknown

Other recruiting trials for Hematopoietic Stem Cell Transplantation

Currently open trials in the same condition.

NCT07400328 — Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients · Phase 2 · recruiting
NCT07349498 — Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation · recruiting
NCT07442513 — Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT · Phase 3 · recruiting
NCT06904053 — Metagenomics Next-generation Sequencing Approach to Detect Microbial DNA/RNA Overtime in Individuals Undergoing Hematopo · recruiting
NCT06708507 — Tissue-resident Immune Cell Subsets in aGVHD · recruiting

Other Nanfang Hospital, Southern Medical University trials

Trials by the same sponsor.

NCT07091994 — A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy · Phase 4 · not yet recruiting
NCT06444022 — hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation · Phase 1 · withdrawn
NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
NCT07481032 — Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients · NA · not yet recruiting
NCT07511894 — Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03689465 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanfang Hospital, Southern Medical University
Last refreshed: 28 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03689465.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing